

URGENT DRUG RECALL — TYPE I

Dantrium Intravenous 20 mg/vial; DIN: 01997572 Voluntary Type I Recall notification

October 16, 2026

Recall reference: Dantrium Intravenous (20 mg/vial DIN: 01997572) Lots 80681, 82413, and 91579

Dear Healthcare Professional:

Please circulate this communication immediately to your Hospital Pharmacy, Anaesthesia Department, Operating Rooms, Emergency Medicine Department, Intensive Care Department, Nursing Department and all other locations holding or potentially holding the affected product.

Knight Therapeutics Inc. (Knight) is initiating a voluntary **Type I recall** from the Canadian market of three lot(s) of DANTRIUM INTRAVENOUS (dantrolene sodium for injection), 20 mg/vial, DIN: 01997572. Health Canada was advised of this recall.

The recalled product can be identified as below:

Table 1: Recall Affected Lots

Product	Lot #	Expiry Date
Dantrium Intravenous (DIN 01997572)	80681	MAY 2027
	82413	AUG 2027
	91579	JUN 2028

Information about Dantrium Intravenous

Dantrium Intravenous (dantrolene sodium for injection, 20 mg/vial) is a sterile injectable product indicated for the treatment of malignant hyperthermia crisis, a rare but life-threatening medical emergency requiring immediate intervention.

Reason for Recall and Health Risk

Visible foreign particulate matter was observed in vials from the affected lots.

Actions required for Healthcare professionals who use Dantrium Intravenous in their practice:

1. Notify all relevant departments and any other facilities or customers to whom you supplied affected lots.
2. Instruct them to identify and quarantine stock and follow the recall instructions ([Refer to Attachment 1 Acknowledgement Card](#)).
3. Complete Acknowledgement Card, even if you hold no affected stock. Keep a copy for your records.
4. Send a copy of the completed Acknowledgement Card to customerservice@knighttx.com within **24 hours**.
5. Arrange the return of the impacted lots listed in Table 1 to your **Wholesaler** to enable the appropriate credit by Knight. Send a copy of the completed Acknowledgement Card to your Wholesaler with the returned product.

If you have any questions on the above, please contact us at:

Tel: 1-844-483-5636

Fax : 1-514-484-4831

Email: medinfo@knighttx.com.

We thank you for your immediate attention and cooperation and apologize for any inconvenience this may have caused.

Please do not hesitate to contact us should you require further information.

Sincerely,

Linda brahmi

Electronically signed by: linda brahmi
Reason: By signing this document with an
electronic signature using Adobe Sign I
am agreeing that I am providing my
approval.
Date: Oct 16, 2026 13:34:38 EDT

Linda Brahmi
Associate Director, Quality Services
Knight Therapeutics Inc.